|57.39||+2.67||+4.88%||Vol 2.11M||1Y Perf -31.57%|
|Jun 24th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||83.44||Analyst Rating||Strong Buy 1.10|
|Potential %||45.39||Finscreener Ranking||★★★+ 51.76|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 53.70|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★+ 49.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||★★ 40.07|
|Price Range Ratio 52W %||13.33||Earnings Rating||Sell|
|Market Cap||5.73B||Earnings Date||26th Jul 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||26th Jul 2022|
|Estimated EPS Next Report||0.98|
|EPS Growth Next 5 Years %||7.30|
|Avg. Weekly Volume||1.43M|
|Avg. Monthly Volume||874.30K|
|Avg. Quarterly Volume||712.69K|
Encompass Health Corporation (NYSE: EHC) stock closed at 57.39 per share at the end of the most recent trading day (a 4.88% change compared to the prior day closing price) with a volume of 2.11M shares and market capitalization of 5.73B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 43178 people. Encompass Health Corporation CEO is Mark J. Tarr.
The one-year performance of Encompass Health Corporation stock is -31.57%, while year-to-date (YTD) performance is -12.06%. EHC stock has a five-year performance of 21.14%. Its 52-week range is between 53.03 and 85.745, which gives EHC stock a 52-week price range ratio of 13.33%
Encompass Health Corporation currently has a PE ratio of 14.40, a price-to-book (PB) ratio of 2.85, a price-to-sale (PS) ratio of 1.08, a price to cashflow ratio of 7.30, a PEG ratio of 2.32, a ROA of 5.96%, a ROC of 9.67% and a ROE of 22.10%. The company’s profit margin is 9.45%, its EBITDA margin is 20.20%, and its revenue ttm is $5.22 Billion , which makes it $52.35 revenue per share.
Of the last four earnings reports from Encompass Health Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.98 for the next earnings report. Encompass Health Corporation’s next earnings report date is 26th Jul 2022.
The consensus rating of Wall Street analysts for Encompass Health Corporation is Strong Buy (1.1), with a target price of $83.44, which is +45.39% compared to the current price. The earnings rating for Encompass Health Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Encompass Health Corporation has a dividend yield of 1.99% with a dividend per share of $1.12 and a payout ratio of 29.00%.
Encompass Health Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 6.42, ATR14 : 1.97, CCI20 : -48.81, Chaikin Money Flow : -0.03, MACD : -2.68, Money Flow Index : 44.90, ROC : -6.49, RSI : 42.44, STOCH (14,3) : 33.88, STOCH RSI : 1.00, UO : 52.10, Williams %R : -66.12), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Encompass Health Corporation in the last 12-months were: Douglas E. Coltharp (Option Excercise at a value of $549 295)
Tue, 03 May 2022 01:46 GMT Analysts Are Bullish on These Healthcare Stocks: Encompass Health (EHC), The Ensign Group (ENSG)- TipRanks. All rights reserved.
Fri, 21 Jan 2022 13:45 GMT Analysts Are Bullish on These Healthcare Stocks: Encompass Health (EHC), Ionis Pharmaceuticals (IONS)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.